Study identifier:5077US/0046
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A multicenter, double-blind, randomized, comparison of the efficacy and safety of Quetiapine Fumarate (SEROQUEL) and placebo in the treatment of agitation associated with dementia.
Alzheimer's disease
Phase 3
No
Quetiapine Fumarate, Placebo
All
333
Interventional
55 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 1st fixed dose | - |
Experimental: 2 2nd fixed dose | - |
Sham Comparator: 3 Placebo | - |